A proposed therapy for the encephalopathies of Reye's syndrome and hepatic encephalopathy.
On the basis of information known about the pathogenesis of Reye's Syndrome and Hepatic Encephalopathy, and the effect of specific pharmacologic agents at the benzodiazepine receptor it is hypothesized that benzodiazepine receptor antagonists and contragonists will be of therapeutic value in those disorders.
D000818:Animals; D001569:Benzodiazepines / Q000037:antagonists & inhibitors*; D006501:Hepatic Encephalopathy / Q000188:drug therapy*; D006801:Humans; D011817:Rabbits; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000378:metabolism; D012202:Reye Syndrome / Q000188:drug therapy* / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000096:biosynthesis
D011963:Receptors, GABA-A; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid